Does photobiomodulation stimulate tumor growth?

Photobiomodulation and Cancer Risk: Examining the Myth That Laser Therapy Feeds Tumor Growth

A belief persists in clinical practice, sometimes stated outright and sometimes simply acted on without discussion, that photobiomodulation (PBM) should never be used anywhere near a patient with a history of cancer, or over any tissue that has ever been irradiated or treated for malignancy. The reasoning usually goes: PBM stimulates cellular metabolism and proliferation, cancer is uncontrolled proliferation, therefore PBM must accelerate cancer. It is a tidy syllogism, and it is also an oversimplification that does not match what the oncology-specific literature actually shows. This article looks specifically at that claim, in the one clinical context where it has been studied in real patients: photobiomodulation for the prevention and treatment of oral mucositis in cancer therapy. It does not attempt to resolve the broader mechanistic debate about how PBM works at the cellular level; that is a separate question. The focus here is narrower and more practical: what does the evidence say about tumor safety when PBM is used in cancer patients, where does that evidence stop, and where does caution become opinion rather than data.

Why the myth exists

The concern is not irrational on its face. PBM is used clinically because it modulates mitochondrial activity and cell signaling in ways associated with increased cellular proliferation, reduced apoptosis, and improved tissue repair in normal cells. Malignant cells are, by definition, cells with dysregulated proliferation and resistance to apoptosis. It is a reasonable hypothesis that a stimulus which favors proliferation and survival in healthy tissue could, in principle, do the same in malignant tissue if the beam reaches it. That hypothesis is exactly why this has been studied directly, rather than left as an assumption in either direction.

What the clinical guideline evidence actually shows

The most directly relevant body of evidence comes from oncology supportive care, specifically the prevention and treatment of oral mucositis, a common and often severe side effect of radiotherapy, chemotherapy, and conditioning regimens for hematopoietic stem cell transplantation (HSCT). The Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) conducted a systematic review specifically to update its clinical practice guidelines on this question, published by Zadik and colleagues in Supportive Care in Cancer: https://pubmed.ncbi.nlm.nih.gov/31286228/. That review, and the full 2020 MASCC/ISOO guideline update published in Cancer by Elad and colleagues (https://pubmed.ncbi.nlm.nih.gov/32786044/), concluded that photobiomodulation is one of the more strongly supported interventions for preventing oral mucositis in specific cancer treatment settings, including HSCT conditioning and head and neck radiotherapy populations. This is established evidence: it comes from a formal systematic review process feeding into a multinational clinical guideline, in patients who are, by definition, undergoing active cancer treatment. If PBM at guideline-specified parameters carried a clear signal of promoting tumor progression in these populations, it is difficult to reconcile that with a guideline recommending its use in exactly these patients.

A separate systematic review by Bensadoun and colleagues in Cancer Medicine looked specifically at the safety and efficacy of PBM therapy in oncology as its primary question: https://pubmed.ncbi.nlm.nih.gov/33107198/. Their synthesis of in vitro, in vivo, and clinical data found PBM used according to established protocols to be safe with respect to tumor behavior and outcomes in the populations studied. This is again established-tier evidence at the level of clinical and in vivo data. It is worth being precise about what “safe” means here: it means no signal of increased tumor progression or recurrence was detected in the studies and follow-up periods reviewed, not that every possible scenario has been tested with long-term oncologic outcome as the primary endpoint. Bensadoun and colleagues themselves note that the question of PBM’s interaction with tumor biology under cytotoxic treatment has had limited direct evaluation and remains, in their words, unresolved for some clinical scenarios. That caveat matters and should not be dropped when this evidence is cited.

Where the picture gets genuinely mixed: in vitro data

The myth’s persistence is helped by real heterogeneity at the cell-culture level, which is a different tier of evidence entirely from the clinical guideline data above. A 2018 study in Frontiers in Oncology found that low-level laser irradiation stimulated proliferation in head and neck squamous cell carcinoma cell lines in a dose-dependent manner, while not producing the same effect in normal epithelial cells: https://pubmed.ncbi.nlm.nih.gov/30211121/. That is a preclinical, cell-culture finding, and it is exactly the kind of result that keeps the underlying hypothesis alive rather than settling it. In apparent contrast, a more recent in vitro study by Shirazian and colleagues, examining parameters specifically matched to those used clinically for oral mucositis, found that irradiation at the lower end of typical mucositis dosing reduced oral squamous cell carcinoma viability and induced apoptosis rather than stimulating growth: https://doi.org/10.1111/php.13997.

Taken together, these two in vitro findings are not necessarily contradictory once wavelength, fluence, irradiance, and cell line are accounted for; they illustrate that the direction of effect on malignant cell lines in a dish is parameter-dependent and cannot be generalized as a single universal answer, in either direction. This is where clinicians should be most careful about how they talk about this evidence. It is tempting to reach for whichever in vitro study supports the position you already hold, whether that is “PBM is always safe” or “PBM always risks stimulating cancer.” Neither blanket statement is supported. The honest position is that in vitro effects on malignant cell lines are dependent on the specific parameters used and the cell line studied, and that this preclinical variability has not translated into a demonstrated clinical safety signal problem in the guideline-supported oral mucositis indication, where dosing is specified and outcomes have been tracked.

The distinction that matters clinically

There is a meaningful difference between two clinical scenarios that this myth tends to blur together. The first is using PBM according to established, guideline-specified parameters in a patient already undergoing defined cancer treatment, for a supportive-care indication with its own evidence base, such as oral mucositis. This is the scenario the MASCC/ISOO guidelines and the Bensadoun review actually address, and the evidence there is reassuring within its scope. The second scenario is applying PBM, at whatever parameters a given device happens to deliver, directly over a lesion of unknown or unconfirmed nature, or over tissue with an undiagnosed mass, simply because the area is convenient to treat for an unrelated complaint such as pain or stiffness. This second scenario has essentially no direct evidence base either way, and treating it as covered by the mucositis literature would be a misapplication of that evidence, not a legitimate extension of it. In this second scenario, avoiding treatment until the lesion has been properly characterized is a matter of basic diagnostic caution, not laser-specific pharmacology, and is best described as sound clinical judgment rather than evidence-based contraindication in the formal sense.

Practical implications for practice

For practitioners treating patients with an active cancer diagnosis for a supportive-care indication with an established evidence base, such as oral mucositis, the literature above does not support withholding PBM on the basis of theoretical tumor-stimulation concerns; the applicable guidelines already weighed that question through systematic review. Practitioners should still follow the specific parameters used in the guideline-referenced protocols rather than assuming any commercially available laser or wavelength is interchangeable, since parameter-dependence is precisely what the in vitro data highlights.

For practitioners considering PBM over a skin lesion, mass, or area of unclear pathology that has not been diagnostically assessed, referral for diagnosis before treatment remains the appropriate step. This is not because PBM has been shown to cause harm in this setting, but because no evidence base exists to support treating over an uncharacterized lesion at all, in either direction, and that absence of evidence is not the same as evidence of safety.

A common mistake worth naming directly is citing “no evidence of harm” as if it means “proven safe in every possible clinical scenario.” The oncology PBM literature currently answers a specific, narrower question well: is PBM at guideline-specified parameters safe when used for supportive care in patients already receiving defined cancer treatment. It has not answered, and does not claim to answer, every hypothetical PBM-and-malignancy scenario a clinician might encounter. Communicating that distinction accurately to colleagues and patients, rather than defaulting to either extreme of the myth, is the responsible position given where the evidence currently stands.

Summary

The claim that photobiomodulation categorically promotes tumor growth is not supported by the clinical and in vivo evidence available for its best-studied oncology application, PBM for oral mucositis, where multinational systematic reviews and clinical practice guidelines describe it as safe and effective within specified parameters. At the same time, preclinical in vitro data on malignant cell lines show genuinely mixed, parameter-dependent effects that have not been fully reconciled, and this should be described to colleagues as emerging and unresolved rather than settled in either direction. Extending the guideline-supported evidence to justify PBM use over any undiagnosed lesion, or invoking the mixed in vitro data to justify blanket avoidance of PBM in any cancer patient regardless of context, are both overreaches of what the current literature actually supports.

About the Author

This analysis was compiled to provide clinicians with clear, evidence-based distinctions in laser protocols. For more resources on clinical laser integration, advanced diagnostics, and evidence-based protocols, visit Ola Laser Acupuncture:

Terms & Conditions
Privacy Policy
Cookies Notice

📧 in**@*****************re.com
☎️ +351 915 698 420

OLA Laser Academy
Instructor: Oren Ziv Ram
NIF: 314055314